PRESS RELEASE
Pixium Vision to attend the 8th Annual Healthtech
investment forum on October 5 & 6, 2021
Paris, France, October 4, 2021 - 18.00 CET- Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent livess, announces today that the management team will participate in the 8th Annual Healthtech Investment Forum taking place on 5th and 6th of October, 2021, digitally. More information about the event can be found here.
To request one-on-one meeting with Pixium Vision please contact Guillaume van Renterghem at
gvanrenterghem@lifesciadvisors.com.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.
For more information:http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Pixium Vision is listed on Euronext Growth Paris.
Euronext ticker: ALPIX - ISIN: FR0011950641
Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Pixium Vision is included in the Euronext GROWTH ALLSHARE index
Contacts | ||
Pixium Vision | Media Relations | Investor Relations |
Offer Nonhoff | LifeSci Advisors | LifeSci Advisors |
Chief Financial Officer | Sophie Baumont | Guillaume van Renterghem |
investors@pixium-vision.com | sophie@lifesciadvisors.com | gvanrenterghem@lifesciadvisors.com |
+33 1 76 21 47 68 | +33 6 27 74 74 49 | +41 76 735 01 31 |
Page 1 / 1
Attachments
- Original document
- Permalink
Disclaimer
Pixium Vision SA published this content on 04 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 October 2021 13:48:10 UTC.